health

US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition

Font size+Author:International Inklings news portalSource:sport2024-05-22 04:44:18I want to comment(0)

WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the b

WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.

The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.

Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.

Related articles
  • The Latest

    The Latest

    2024-05-22 04:35

  • Book on Value of Xi Jinping's Economic Thought Published

    Book on Value of Xi Jinping's Economic Thought Published

    2024-05-22 04:14

  • Xi Sends Greetings to Working People Nationwide Ahead of Int'l Workers' Day

    Xi Sends Greetings to Working People Nationwide Ahead of Int'l Workers' Day

    2024-05-22 03:46

  • View of spring in Beijing

    View of spring in Beijing

    2024-05-22 02:04

Netizen comments